Qualigen Therapeutics, Inc. (QLGN)
$
3.64
-0.16 (-4.40%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutic products aimed at treating cancer and infectious diseases. The cost of revenue for the company is $5,209,250.00 showcasing its production and operational expenses. The operating expenses amount to $6,095,607.00 encompassing various operational costs incurred in the pursuit of its development goals. The financial data pertains to the fiscal year 2023 and the earnings per share (EPS) is reported at -$2.46 indicating the company's profitability on a per-share basis. Furthermore, the diluted EPS is -$2.46 accounting for potential share dilution, which provides a clearer picture of shareholder value. The company is currently advancing several clinical candidates, including QN-302 for pancreatic ductal adenocarcinoma, QN-247, a DNA-coated gold nanoparticle targeting a range of cancers, RAS-F, a small-molecule inhibitor designed to block RAS mutations and inhibit tumor formation, and the STARS blood cleansing system, which aims to remove tumor-produced compounds and viruses from patients' blood. Established in 1996, Qualigen Therapeutics is headquartered in Carlsbad, California. The stock of Qualigen Therapeutics is currently affordable at $3.41 making it a suitable option for budget-conscious investors. Despite its competitive positioning, the stock has a low average trading volume of 63,530.00 indicating lower market activity, which may reflect on its liquidity. With a market capitalization of $2,680,609.00 the company is classified as a small-cap player, highlighting its potential for growth within the industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. As the company progresses in its development of groundbreaking therapies, it navigates the complexities of the biotechnology landscape while appealing to investors looking for opportunities in emerging markets.
Is Qualigen Therapeutics, Inc. (QLGN) a good investment?
Investing in Qualigen Therapeutics, Inc. (QLGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bullish outlook. Always conduct your own research before investing.
What is Qualigen Therapeutics, Inc. (QLGN)'s stock forecast?
Analysts predict Qualigen Therapeutics, Inc. stock to fluctuate between $2.96 (low) and $29.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Qualigen Therapeutics, Inc.'s market capitalization?
As of 2025-04-02, Qualigen Therapeutics, Inc.'s market cap is $2,680,609, based on 736,431 outstanding shares.
How does Qualigen Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Qualigen Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Qualigen Therapeutics, Inc. (QLGN) stock?
To buy Qualigen Therapeutics, Inc. (QLGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QLGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Qualigen Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Qualigen Therapeutics, Inc. stock ever split?
Qualigen Therapeutics, Inc.'s last stock split was 1:50 on 2024-11-05.
How did Qualigen Therapeutics, Inc. perform in the last earnings report?
Revenue: $5,204,755 | EPS: -$2.46 | Growth: -55.11%.
Where can I find Qualigen Therapeutics, Inc.'s investor relations reports?
Visit https://www.qualigeninc.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Qualigen Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Qualigen Therapeutics, Inc. stock?
All-time high: $2,217 (2021-02-16) | All-time low: $2.96 (2025-01-29).
What are the key trends affecting Qualigen Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
4 months ago
New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations.
globenewswire.com
5 months ago
CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301.
globenewswire.com
6 months ago
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives.
globenewswire.com
6 months ago
CARLSBAD, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel (“Panel”) has granted an extension for the continued listing of the Company, subject to the Company evidencing compliance with all applicable criteria for continued listing on The Nasdaq Capital Market by November 19, 2024. The Company is diligently working to fulfill the requirements set forth by the Panel to ensure the Company's continued listing on Nasdaq.
globenewswire.com
7 months ago
New York, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of registered direct offering (the “Offering”) of (i) 14,724,058 shares of common stock priced at $0.130 per share, with pre-funded warrants exercisable for 11,972,754 shares with respect to the registered direct offering for its client Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer.
globenewswire.com
7 months ago
CARLSBAD, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per share with an exercise price of $0.001 per share (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable upon issuance and will remain exercisable until all the Pre-Funded Warrants are exercised in full.
globenewswire.com
7 months ago
CARLSBAD, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at a public offering price of $0.13 per Share and pre-funded warrants to purchase up to 11,972,754 Shares at a price of $0.129 per pre-funded warrant with an exercise price of $0.001 per share (the “Pre-Funded Warrants”). The Pre-Funded Warrants are exercisable upon issuance and will remain exercisable until exercised in full. The closing of the offering is expected to occur on or about September 6, 2024, subject to the satisfaction of customary closing conditions.
investorplace.com
9 months ago
Qualigen Therapeutics (NASDAQ: QLGN ) stock is falling on Monday as the clinical-stage therapeutics company's shares come off of a massive rally on Friday. That Friday rally resulted in shares of QLGN stock closing out normal trading hours up 109.2%.
investorplace.com
9 months ago
Qualigen (NASDAQ: QLGN ) stock is rocketing higher on Friday after the clinical-stage therapeutics company secured a new loan. Qualigen reached an agreement with an investor for a $2 million Senior Note due July 8, 2025 with an 18% annual interest rate.
investorplace.com
9 months ago
Qualigen Therapeutics (NASDAQ: QLGN ) stock is sliding lower on Monday as the clinical-stage therapeutics company's shares come off of a rally on Friday. That rally saw shares of QLGN stock soar more than 59% higher during normal trading hours.
See all news
